Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment.

ABSTRACT: Acute myeloid leukemia (AML) treatment has always been a challenge to the treating physician. Continuous efforts are being made to improve treatment outcomes in AML. CPX-351 is a pharmacologic advancement in this direction. It is a liposomal fixed drug combination of cytarabine and daunorubicin. Early studies indicate that it will play a big role in AML treatment. This is a short review about this drug.

SUBMITTER: Raut LS 

PROVIDER: S-EPMC4382783 | biostudies-literature | 2015 Jan-Mar

REPOSITORIES: biostudies-literature